The Pink Pill: A Fight for Women's Sexual Desire

The documentary 'The Pink Pill' highlights the challenges in providing access to flibanserin, a medication for low female libido. Initially conceived as an antidepressant by Boehringer Ingelheim, flibanserin demonstrated efficacy in treating Hypoactive Sexual Desire Disorder (HSDD) by affecting brain neurotransmitters.

In 2015, the US FDA approved flibanserin, marketed as Addyi, for premenopausal women with HSDD. However, many women remain unaware of its existence, partly due to a lack of comprehensive female sexual health education in medical curricula. The drug's approval process was marked by controversy, with comparisons drawn to the swift acceptance of Viagra for men.

Cindy Eckert, a pharmaceutical entrepreneur, acquired flibanserin and renamed it Addyi. The FDA's review, assigned to its urology division and citing side effects like dizziness and nausea, led to initial rejection. Critics argued that the FDA applied a paternalistic and sexist double standard, dismissing the benefits for women while readily accepting similar side effects for male-oriented drugs.

Despite facing backlash and skepticism, the FDA eventually approved Addyi in 2015, albeit with a stringent black box warning and prescription requirements. Pharmaceutical giant Valeant later acquired the drug, significantly increased its price, and then shelved it, making it largely inaccessible.

Eckert has since repurchased Addyi and returned it to the market. Proponents argue that the drug's restrictive warnings and high cost, coupled with numerous approved treatments for male sexual dysfunction, highlight a persistent bias against addressing female sexual pleasure and choice. The film concludes by linking the fight for Addyi to broader issues of bodily autonomy and reproductive rights.